59 results about "Drug Dependency" patented technology

The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U/kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.

A vibrational instrument which is therapeutically beneficial in treating the person suffering from afflictions such as headache, sinus congestion and pressure, and withdrawal due to drug dependency includes a member capable of transmitting vibrational waves through the teeth, jaw and sinus tissue for disposal between teeth of the person. A method of treatment is also provided.

A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic defects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist. In another embodiment, the drug or its other agonist is first administered and the antagonist is self-administered by a subject in a manner which mimics the use of the drug thereby counter-conditioning the drug user to the stimuli associated with the normal administration of the drug. The invention further provides a method of therapeutically treating psychophysiologic diseases and disorders involving neuronal dysregulation. The method additionally provides a pharmacologic composition for the treatment and reduction of drug dependence and which relies upon a combination of an agonist and antagonist.

The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone.

The present disclosure is directed to modulators of opiate- and/or NMDA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of pain, anxiety, neurodegeneration, drug dependence, coughing, muscular tension, and/or glaucoma and any other condition in which it is beneficial to modulate an opiate- and/or NMDA receptor.

Mice in which OCT3 expression is suppressed were successfully constructed by administering antisense against OCT3 gene into the brain. Mice in which OCT3 expression is suppressed display phenotypes related to mental disorders such as anti-depression and anti-anxiety, and therefore the mice can be applied to the screening of therapeutic agents for mental disorders. In addition, substances suppressing the OCT3 expression or function were shown to be in fact effective as therapeutic agents for depression and anxiety neuroses.

The invention relates to an irinotecan hydrochloride injection consisting of irinotecan hydrochloride (15-25g/L), sorbierite (17.5-22.5g/L), and the balance of phosphoric acid and injection water, wherein the phosphoric acid adjusts the pH of the injection to 3.0-3.8. The invention also relates to a preparation method of the irinotecan hydrochloride injection. Compared with the prior art, the irinotecan hydrochloride injection disclosed by the invention has the following beneficial effects: (1) the untoward effect is reduced; as shown in an animal test, the irinotecan hydrochloride injection disclosed by the invention can greatly reduce the untoward effect of delayed-onset diarrhea caused by irinotecan, which has an active promotion effect on the drug dependency and treatment effect of cancer patients; (2) the stability is high, as shown in an acceleration test, the character, acidity, solution clarity and color, insoluble particles, visible foreign matters, moisture, related substance and content of the irinotecan hydrochloride injection meet the regulations; and (3) the preparation method is simple and is favorable to the industrial mass production.

A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D₃ receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

The invention discloses an external drug for treating insomnia. The external pharmaceutical is packaged by a drug bag, and comprises radix codonopsitis 1.5-7.5g, largehead atractylodes 1-5g, milk vetch 1.5-7.5g, best poria 1.5-7.5g, polygala root 1-5g, spine data seed 2-10g, angelica 1-5g, costus root 1-5g, vermilion 0.5-2.5g, magnet 2-10g, six medicated leaven1.5-7.5g, tuber fleeceflower stem 1.5-7.5g, albizia bark 1.5-7.5g, dragon bone 2-10g, oyster 2-10g, schisandra fruit 1-5g, eucommia bark 1.5-7.5g, bugbane rhizome 1-5g, and licorice 1-5g. The preparation method includes pulverizing the materials into powder; and packaging in a drug bag made of fabric. The external drug has the advantages of no toxic and side effect, low cost, remarkable therapeutic effect, convenient application and no damage, allergy and irritation to skin, and caused no drug dependency of patients.

A remedy for drug dependence in which the active ingredient is an opioid kappa receptor agonist in which the typical compound is represented by the following formula. An opioid kappa receptor agonist in accordance with the present invention is different from a conventional symptomatic treatment manner for the drug dependence. The opioid kappa receptor agonist in accordance with the present invention is a promising remedy for drug dependence with little adverse effects which affects expression mechanism of a reward effect so as to inhibit development both psychic dependence and physical dependence.

The present invention relates to a Chinese medicine composition for treating partial eclipse and anorexia of children, a preparation and a manufacturing method thereof. The Chinese medicine composition belongs to the field of Chinese medicine science and comprises the raw medicinal herbs by weight: 1-10 parts of bighead atractylodes rhizome, 10-20 parts of cardamom, 10-15 parts of finger citron, 2-3 parts of clove, 2-8 parts of citrus reticulate blanco, 3-8 parts of amomum villosum, 10-30 parts of radish seeds, 10-15 parts of agastache rugosa and 2-10 parts of banksia rose. The Chinese medicine composition of the invention has excellent curative effect for treating partial eclipse and anorexia of children. Furthermore the optimal preparation form of the invention is external-used powder and has the advantages of simple preparing method and convenient using of directly pasting. The Chinese medicine composition of the invention has no toxic or side effect or drug dependency, and can be used for a long time.

A vibrational instrument which is therapeutically beneficial in treating the person suffering from afflictions such as headache, sinus congestion and pressure, and withdrawal due to drug dependency includes a member capable of transmitting vibrational waves through the teeth, jaw and sinus tissue for disposal between teeth of the person. A method of treatment is also provided.

The invention provides a traditional Chinese medicine composition for treating light-headedness, and relates to the technical field of Chinese herbal medicines. The formula of the traditional Chinese medicine composition comprises 20-50 parts of glossy privet fruit, 20-50 parts of mulberry fruit, 5-15 parts of ligusticum wallichii, 10-30 parts of herba ecliptae and 10-30 parts of motherwort in a weight ratio. The glossy privet fruit, the mulberry fruit, the ligusticum wallichii, the herba ecliptae and the motherwort are added to water in proportion and decocted with water and a patient can take the decoction which is cooled to warm. The traditional Chinese medicine composition can be used for effectively treating the light-headedness and is capable of avoiding various side effects and drug dependency often caused by the long-term taking of medicines for treating illness; the used materials are common food in daily life and low in cost; the disease is treated when people enjoy delicious food; and by taking the traditional Chinese medicine composition, the pains caused by injection, medicine taking even operation can be avoided.

The invention discloses a drug for preventing respiratory infectious diseases. The drug comprises the following components in parts by weight: 4 to 15 parts of tuber of dwarf lilyturf, 5 to 16 parts of cortex lycii, 5 to 15 parts of bighead atractylodes rhizome, 2 to 12 parts of dragon's blood, 5 to 15 parts of safflower, 2 to 10 parts of honeysuckle flower, 2 to 10 parts of fructus forsythiae, 2 to 13 parts of isatis root, 1 to 6 parts of radix bupleuri, 2 to 10 parts of radix scutellariae, 6 to 12 parts of apricot kernel, 10 to 18 parts of radix codonopsis, and 2 to 13 parts of imperata rhizome. The formula of the drug is reasonable. The drug has a prominent preventive effect on respiratory infectious diseases, and the effect is long lasting. Moreover, the drug does not have any side or toxic effect. The drug dependency is not generated even if the patients take the drug for a long term.

Provided is an instrument for alleviating addictive drug craving which can be safely administered to an addictive drug-dependent patient by a definite method in practice without causing any undesirable effects on therapy and terminate a series of behaviors through the administration so as to achieve an excellent effect on the therapy for alleviating addictive drug craving. An instrument for alleviating addictive drug craving (11) which comprises a pseudo injection agent (31) enclosed in a pseudo container (21). To the outer face of the pseudo container (21), which is an ampule-shaped container being similar in appearance and structure to a container of an addictive drug (X), a pseudo injection agent label (41), which is almost the same in constitution to a product label of the container of the addictive drug (X) except having the term “PSEUDO” added hereto, is attached. The pseudo injection agent (31) is similar in appearance to an injection agent of the addictive drug (X) but free from the active ingredient of the addictive drug (X).